TransMedics Is Down 40%. Is the Margin Story Breaking?

AI-generated source summary

TransMedics (TMDX) is a medical technology company with a market cap of $2.38B, trading at $69.02. The company's P/E ratio is 15.82, and it has shown revenue growth of 37% year-over-year for the full year 2025, with total revenue reaching $665.5 million. The company's OCS platform offers a unique service for organ transplantation, keeping organs viable outside the body during transport, which addresses key challenges in the industry like organ quality, availability, and process efficiency. Despite recent stock price declines of 40% in the last month and 44% in the last year, the company's core business of providing organ transport infrastructure services is showing growth. The company is investing heavily in aviation, logistics, clinical teams, and international expansion, which strengthens its competitive moat. Analysts have a consensus rating of 'Moderate Buy' with a mean target price of $117.89, suggesting a potential upside of 70% from current levels. The current analysis considers the stock a potential buy around $50-$60, with a failure bound at $50, anticipating a rebound based on the long-term potential of its integrated infrastructure model and the demand for improved organ transplantation solutions.

AI-generated summary based on the source content.